Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Overview[ - collapse ][ - ]
| Purpose | Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard chemotherapy in the treatment of early stage node positive or otherwise high-risk breast cancer. If this should prove to be a tolerable regimen for patients, this would provide rationale for further studies in a larger randomized fashion. |
|---|---|
| Condition | Breast Cancer |
| Intervention | Drug: Doxorubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Sorafenib |
| Phase | N/A |
| Sponsor | SCRI Development Innovations, LLC |
| Responsible Party | SCRI Development Innovations, LLC |
| ClinicalTrials.gov Identifier | NCT00544167 |
| First Received | October 15, 2007 |
| Last Updated | March 25, 2013 |
| Last verified | March 2013 |
Tracking Information[ + expand ][ + ]
| First Received Date | October 15, 2007 |
|---|---|
| Last Updated Date | March 25, 2013 |
| Start Date | May 2007 |
| Estimated Primary Completion Date | April 2011 |
| Current Primary Outcome Measures | The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0. [Time Frame: 18 Months] [Designated as safety issue: Yes] |
| Current Secondary Outcome Measures | Not Provided |
Descriptive Information[ + expand ][ + ]
| Brief Title | Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer |
|---|---|
| Official Title | A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer |
| Brief Summary | Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard chemotherapy in the treatment of early stage node positive or otherwise high-risk breast cancer. If this should prove to be a tolerable regimen for patients, this would provide rationale for further studies in a larger randomized fashion. |
| Detailed Description | Primary Objectives The primary objective is to assess the safety and tolerability of doxorubicin / cyclophosphamide followed by paclitaxel in combination with sorafenib in patients with early stage node positive or otherwise high-risk breast cancer. Secondary Objectives The secondary objectives are to assess activity in the form of recurrence-free-interval, distant recurrence-free interval,and overall survival in this pilot study of doxorubicin / cyclophosphamide followed by paclitaxel in combination with sorafenib in patients with early stage node positive or otherwise high-risk breast cancer. |
| Study Type | Interventional |
| Study Phase | N/A |
| Study Design | Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Condition | Breast Cancer |
| Intervention | Drug: Doxorubicin Other Names: AdriamycinDrug: Cyclophosphamide Other Names: CytoxanDrug: Paclitaxel Other Names: TaxolDrug: Sorafenib Other Names: Nexavar |
| Study Arm (s) | Experimental: Intervention All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated. |
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Completed |
|---|---|
| Estimated Enrollment | 45 |
| Estimated Completion Date | April 2011 |
| Estimated Primary Completion Date | January 2008 |
| Eligibility Criteria | Inclusion Criteria: - Patients must have histologically-confirmed breast cancer with an interval between definitive surgery that includes axillary lymph node involvement assessment and initiation of study treatment of less than or equal to 84 days. - Definitive surgery - either mastectomy with axillary node involvement assessment, or breast conserving surgery with axillary node assessment. Margins of resected specimen must be free of invasive disease and/or ductal carcinoma in situ (DCIS). - Stage I, II, IIIA, and IIIC (T1-3, N3a only). Patients must be either lymph node positive or high-risk node negative. - Age > 18 years. - ECOG performance status 0 or 1. - Normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF) by Echocardiography or MUGA scan and electrocardiogram (ECG) within 35 days prior to initiation of study treatment. - Patients must have adequate bone marrow function - Patients must have normal liver function ( - Serum creatinine <= 2mg/dl - INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored. Exclusion Criteria: - Prior systemic anticancer therapy for breast cancer (immunotherapy, chemotherapy, hormonal therapy). - Patients with HER2 positive breast cancer as determined by FISH or IHC3+ standing are ineligible for this trial. - Prior anthracycline or taxane therapy. - Prior radiation therapy for breast cancer. - Bilateral invasive disease. - Pre-existing motor or sensory neurotoxicity of a severity ≥ 2 by NCI CTCAE v 3.0 criteria. - Cardiac disease that includes: myocardial infarction; angina, congestive heart failure, arrhythmia; valvular heart disease; cardiomegaly on chest imaging or ventricular hypertrophy on ECG - unless the LVEF is within normal range for the institution; patients with poorly controlled hypertension (defined as systolic blood pressure > 150 and /or diastolic blood pressure > 100 mmHg on antihypertensive medications); patients who receive medications for angina, arrhythmias, or congestive heart failure. - Current therapy with raloxifene, tamoxifen or other selective estrogen receptor modulator - Concurrent treatment with ovarian hormonal replacement therapy. - History of prior malignancy within 5 years with the exception of skin cancer or cervical carcinoma in situ. - Women who are pregnant (positive pregnancy test) or breast feeding. Subjects of childbearing potential must use effective birth control measures during treatment. - Treatment with a non-approved or investigational drug within 30 days before day 1 of trial treatment. - Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis. - Thrombotic or embolic events such as a stroke and transient ischemic attack within the past 6 months. - Pulmonary hemorrhage/bleeding event ≥ NCI CTCAE v3.0 Grade 2 within 4 weeks of first dose of study drug. - Any other hemorrhage/bleeding event ≥ NCI CTCAE v3.0 Grade 3 within 4 weeks of first dose of study drug. |
| Gender | Female |
| Ages | 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | United States |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT00544167 |
|---|---|
| Other Study ID Numbers | SCRI BRE 112 |
| Has Data Monitoring Committee | No |
| Information Provided By | SCRI Development Innovations, LLC |
| Study Sponsor | SCRI Development Innovations, LLC |
| Collaborators | Bayer |
| Investigators | Study Chair: Denise Yardley, M.D. SCRI Development Innovations, LLC |
| Verification Date | March 2013 |
Locations[ + expand ][ + ]
| Integrated Community Oncology Network | Jacksonville, Florida, United States, 32256 |
|---|---|
| Florida Hospital Cancer Institute | Orlando, Florida, United States, 32804 |
| Consultants in Blood Disorders and Cancer | Louisville, Kentucky, United States, 40207 |
| Grand Rapids Clinical Oncology Program | Grand Rapids, Michigan, United States, 49503 |
| Methodist Cancer Center | Omaha, Nebraska, United States, 68114 |
| Chattanooga Oncology Hematology Associates | Chattanooga, Tennessee, United States, 37404 |
| Tennessee Oncology, PLLC | Nashville, Tennessee, United States, 37023 |
| Peninsula Cancer Institute | Newport News, Virginia, United States, 23601 |